A risk-based approach to optimize autologous hematopoietic stem cell (HSC) collection with the use of plerixafor

Bone Marrow Transplantation

Volumn 47, Issue 4, 2012, Pages 483-487

  Abhyankar, S ^a   Dejarnette, S ^b   Aljitawi, O ^a   Ganguly, S ^a   Merkel, D ^b   McGuirk, J ^a  

^a UNIVERSITY OF KANSAS MEDICAL CENTER   (United States)

^b UNIVERSITY OF KANSAS HOSPITAL   (United States)

Author keywords

autologous; cell; mobilization; plerixafor; stem; transplant

Indexed keywords

CD34 ANTIGEN; GRANULOCYTE COLONY STIMULATING FACTOR; PLERIXAFOR;

ADULT; AGED; ARTICLE; CELL COUNT; CONTROLLED STUDY; CULTURE OPTIMIZATION; FEMALE; HEMATOPOIETIC STEM CELL; HUMAN; MAJOR CLINICAL STUDY; MALE; PATIENT IDENTIFICATION; PATIENT SELECTION; PRIORITY JOURNAL; STEM CELL MOBILIZATION;

ADULT; AGED; ANTI-HIV AGENTS; ANTIGENS, CD34; CELL SEPARATION; FEMALE; GRANULOCYTE COLONY-STIMULATING FACTOR; HEMATOPOIETIC STEM CELL MOBILIZATION; HEMATOPOIETIC STEM CELL TRANSPLANTATION; HEMATOPOIETIC STEM CELLS; HETEROCYCLIC COMPOUNDS; HUMANS; MALE; MIDDLE AGED; RISK FACTORS; TRANSPLANTATION, AUTOLOGOUS;

EID: 84859467357     PISSN: 02683369     EISSN: 14765365     Source Type: Journal    
DOI: 10.1038/bmt.2011.133     Document Type: Article

References (20)

1. Blade J, Rosinol L, Cibeira MT, Rovira M, Carreras E. Hematopoietic stem cell transplantation for multiple myeloma beyond 2010. Blood 2010; 115: 3655-3663.
2. Vose JM, Anderson JR, Kessinger A, Bierman PJ, Coccia P, Reed EC et al. High-dose chemotherapy and autologous hematopoietic stem-cell transplantation for aggressive non-Hodgkin's lymphoma. J Clin Oncol 1993; 11: 1846-1851. (Pubitemid 23304606)
3. Wright DE, Cheshier SH, Wagers AJ, Randall TD, Christen-sen JL, Weissman IL. Cyclophosphamide/granulocyte colony-stimulating factor causes selective mobilization of bone marrow hematopoietic stem cells into the blood after M phase of the cell cycle. Blood 2001; 97: 2278-2285. (Pubitemid 32291472)
4. Morris CL, Siegel E, Barlogie B, Cottler-Fox M, Lin P, Fassas A et al. Mobilization of CD34+ cells in elderly patients (4/70 years) with multiple myeloma: influence of age, prior therapy, platelet count and mobilization regimen. Br J Haematol 2003; 120: 413-423. (Pubitemid 36241497)
5. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490-499.
6. Moskowitz CH, Glassman JR, Wuest D, Maslak P, Reich L, Gucciardo A et al. Factors affecting mobilization of peripheral blood progenitor cells in patients with lymphoma. Clin Cancer Res 1998; 4: 311-316. (Pubitemid 28122743)
7. Kalatskaya I, Berchiche YA, Gravel S, Limberg BJ, Rosenbaum JS, Heveker N. AMD3100 is a CXCR7 ligand with allosteric agonist properties. Mol Pharmocol 2009; 75: 1240-1247.
8. Lapidot T, Petit I. Current understanding of stem cell mobilization: the roles of chemokines, proteolytic enzymes, adhesion molecules, cytokines, and stromal cells. Exp Hematol 2002; 30: 973-981. (Pubitemid 35286613)
9. Broxmeyer HE, Orschell CM, Clapp DW, Hangoc G, Cooper S, Plett PA et al. Rapid mobilization of murine and human hematopoietic stem and progenitor cells with AMD3100, a CXCR4 antagonist. J Exp Med 2005; 201: 1307-1318. (Pubitemid 40629073)
10. Calandra G, McCarty J, McGuirk J, Tricot G, Crocker SA, Badel K et al. AMD3100 plus G-CSF can successfully mobilize CD34+ cells from non-Hodgkin's lymphoma, Hodgkin's disease and multiple myeloma patients previously failing mobilization with chemotherapy and/or cytokine treatment: compassionate use data. Bone Marrow Transplant 2008; 41: 331-338. (Pubitemid 351330727)
11. DiPersio JF, Stadtmauer EA, Nademanee A, Micallef IN, Stiff PJ, Kaufman JL et al. Plerixafor and G-CSF versus placebo and G-CSF to mobilize hematopoietic stem cells for autologous stem cell transplantation in patients with multiple myeloma. Blood 2009; 113: 5720-5726.
12. DiPersio JF, Micallef IN, Stiff PJ, Bolwell BJ, Maziarz RT, Jacobsen E et al. Phase III prospective randomized double-blind placebo-controlled trial of plerixafor plus granulocyte colony-stimulating factor compared with placebo plus granu-locyte colony-stimulating factor for autologous stem-cell mobilization and transplantation for patients with non-Hodgkin's lymphoma. J Clin Oncol 2009; 27: 4767-4773.
13. Demirer T, Ilhan O, Ayli M, Arat M, Dagli M, Ozcan M et al. Monitoring of peripheral blood CD34+ cell counts on the first day of apheresis is highly predictive for efficient CD34+ cell yield. Ther Apher 2002; 6: 384-389. (Pubitemid 35192329)
14. Costa LJ, Alexander ET, Hogan KR, Schaub C, Fouts TV, Stuart RK. Development and validation of a decision-making algorithm to guide the use of plerixafor for autologous hematopoietic stem cell mobilization. Bone Marrow Transplant 2011; 46: 64-69.
15. Tornatta J, Maciejewski JJ, Nathan S, McLeod BC, Rhoades D, Palaparthy S. Efficacy of administration of plerixafor (Mozobils) at 5:00 PM for stem cell mobilization (SCM) in patients receiving autologous stem cell transplant. Blood (ASH Annual Meeting Abstracts) 2009; 114: 3218.
16. Burger JA, Peled A. CXCR4 antagonists: targeting the microenvironment in leukemia and other cancers. Leukemia 2009; 23: 43-52.
17. Wuchter P, Ran D, Bruckner T, Schmitt T, Witzens-Harig M, Neben K et al. Poor mobilization of hematopoietic stem cells-definitions, incidence, risk factors, and impact on outcome of autologous transplantation. Biol Blood Marrow Transplant 2010; 16: 490-499.
18. Sutherland DR, Anderson L, Keeney M, Nayar R, Chin-Yee I. The ISHAGE guidelines for CD34 positive cell determination by flow cytometry. Hematotherapy 1996; 5: 213-226.
19. Yang SH, Wang TF, Tsai HH, Lin TY, Wen SH, Chen SH. Preharvest hematopoietic progenitor cell counts predict CD34+ cell yields in granulocyte-colony-stimulating factor-mobilized peripheral blood stem cell harvest in healthy donors. Transfusion 2010; 50: 1088-1095.
20. Shaughnessy P, Islas-Ohlmayer M, Murphy J, Hougham M, Macpherson J, Winkler K et al. Cost and clinical analysis of autologous hematopoietic stem cell mobilization with G-CSF and plerixafor compared to G-CSF and cyclophosphamide. Biol Blood Marrow Transplant 2011; 17: 729-736.